Oxol

Oxol

oxaliplatin

Manufacturer:

Venus Remedies

Distributor:

Cosma Medical
Concise Prescribing Info
Contents
Oxaliplatin
Indications/Uses
In combination w/ 5-fluorouracil (5-FU) & leucovorin for metastatic CRC; unresectable advanced or metastatic gastric cancer; unresectable hepatocellular carcinoma; adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor.
Dosage/Direction for Use
IV infusion Adult Metastatic CRC 85 mg/m2 every 2 wk. Unresectable advanced or metastatic gastric cancer Combination w/ infusional 5-FU & folinic acid: 100 mg/m2 every 2 wk. Combination w/ fluorouracil & leucovorin (FLO regimen): oxaliplatin 85 mg/m2 + fluorouracil 2,600 mg/m2 & leucovorin 200 mg/m2 every 2 wk; modified FOLFOX regimen: oxaliplatin 85 mg/m2 + fluorouracil 1,000 mg/m2 & leucovorin 200 mg/m2 every 2 wk. Combination w/ epirubicin & capecitabine or fluorouracil (EOX or EOF regimen): oxaliplatin 130 mg/m2 + epirubicin 50 mg/m2 & capecitabine 625 mg/m2 or fluorouracil 200 mg/m2. Unresectable hepatocellular carcinoma 85 mg/m2 in combination w/ 5-FU & folinic acid every 2 wk. Adjuvant setting 85 mg/m2 every 2 wk for 12 cycles (6 mth). Severe renal impairment, persistent grade 2 neurosensory events 65 mg/m2.
Contraindications
Allergy to oxaliplatin or other platinum compd.
Special Precautions
Hypersensitivity & anaphylactic/anaphylactoid reactions. Discontinue in case of extravasation; unexplained resp symptoms eg, non-productive cough, dyspnea, crackles or radiological pulmonary infiltrates. Acute & persistent peripheral sensory neuropathy. Exposure to cold or cold objects may precipitate acute neurosensory toxicity. Fever w/ persistent diarrhea or evidence of infection; vomiting, signs of dehydration, cough or breathing difficulties. Monitor WBC, Hb, platelet count, AST, ALT, bilirubin & creatinine before each treatment cycle. Severe renal & hepatic impairment. Avoid becoming pregnant while on treatment. Lactation. Ped.
Adverse Reactions
Anemia, diarrhea, emesis, fatigue, increase in transaminases & alkaline phosphatase, nausea, neutropenia, peripheral sensory neuropathy, stomatitis & thrombocytopenia.
Drug Interactions
Increased plasma conc of 5-FU. Decreased clearance w/ nephrotoxic compd. Avoid use w/ intravesical BCG, deferiprone, dipyrone, natalizumab, pimecrolimus, topical tacrolimus, live vaccines. Increased effect/toxicity of clozapine, deferiprone, fingolimod, leflunomide, natalizumab, highest & moderate risk QTc-prolonging agents, taxane derivatives, tofacitinib, topotecan, live vaccines. Increased levels/effects w/ bupropion, ophth chloramphenicol, denosumab, dipyrone, mifepristone, ocrelizumab, palifermin, pimecrolimus, promazine, roflumilast, topical tacrolimus, trastuzumab. Decreased levels/effects of intrevesical BCG, Coccidioides immitis skin test, fosphenytoin-phenytoin, lenograstim, lipegfilgrastim, nivolumab, pidotimod, sipuleucel-T, tertomotide, inactivated & live vaccines. Decreased levels/effects w/ Echinacea.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01XA03 - oxaliplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.
Presentation/Packing
Form
Oxol infusion 100 mg/50 mL
Packing/Price
1's
Form
Oxol infusion 50 mg/25 mL
Packing/Price
1's
Sign up for Free to continue reading
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in